Articles

Resource utilization associated with the management of potential interactions between direct-acting antivirals for chronic hepatitis C treatment and cardiovascular and central nervous system drugs

Evaluation of the additional actions and resource utilization required for the management of potential drug-drug interactions in HCV patients showing cardiovascular and central nervous system comorbidities, treated with sofosbuvir/velpatasvir compared to glecaprevir/ pibrentasvir in routine clinical practice in Spain.


Download PDF
Skip to content
Privacy Summary

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.